Tafazzin Polyclonal Antibody, HRP Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-15504R-HRP |
| Product Name | Tafazzin Polyclonal Antibody, HRP Conjugated |
| Applications |
WB
ELISA
IHC-P
IHC-F
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep |
| Specifications | |
| Conjugation | HRP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Tafazzin |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 6901 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | Barth syndrome; Cardiomyopathy dilated 3A X linked; EFE2; Endocardial fibroelastosis 2; Protein G4.5; Tafazzin; TAZ; TAZ protein; TAZ protein; TAZ_HUMAN. |
| Background | This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |